Table 1.
Characteristics of study participants.
| PID Group | Total number of patients | Clinical diagnosis (number of patients) | Age | Gender | |
|---|---|---|---|---|---|
| Male | Female | ||||
| Group I (“Combined PID”)Immunodeficiencies affecting cellular and humoral immunity | 17 | D81 Combined immunodeficiencies (17) | 0–12 months 1–6 years 6–12 years 12–18 years |
9 2 1 0 |
5 0 0 0 |
| Group II (“Syndromic PID”)CID with associated or syndromic features |
80 | D82 Immunodeficiency associated with other major defects (13) D82.1 Di George syndrome (39) D82.4 Hyperimmunoglobulin E syndrome (5) D84.8 Other specified immunodeficiencies (15) G11.3 (8) |
0–12 months 1–6 years 6–12 years 12–18 years |
7 26 10 4 |
9 17 6 3 |
| Group III (“Antibody PID”)Predominantly antibody deficiencies |
148 | D80.0 Immunodeficiency with predominantly antibody defects (4) D80.1 Non-familial hypogammaglobulinaemia (47) D80.2 Selective deficiency of immunoglobulin A (34) D80.3 Selective deficiency of immunoglobulin G (24) D80.4 Selective deficiency of immunoglobulin M (1) D80.5 Immunodeficiency with increased immunoglobulin M (4) D83 Common variable immunodeficiency (34) |
0–12 months 1–6 years 6–12 years 12–18 years |
6 21 28 38 |
2 17 21 13 |
| Control group (Healthy children) | 226 | No clinical diagnosis of PID | 0–12 months 1–6 years 6–12 years 12–18 years |
9 41 36 25 |
5 48 33 29 |
All codes and diagnoses are in accordance with international classification of diseases, 10th revision (ICD-10).